Document:

CHINA BIOLOGIC PRODUCTS, INC.

DIRECTOR AGREEMENT

 

THIS AGREEMENT (The “Agreement”)
is made as of the 4th day of May, 2014 and is by and between China Biologic Products, Inc., a Delaware corporation (hereinafter
referred to as the “Company”), and Mr. Dai Feng (hereinafter referred to
as the “Director”).

 

BACKGROUND

 

The Board of Directors
of the Company desires to appoint the Director to fill an existing vacancy due to resignation of Dr. Bing Li and to have the Director
perform the duties of a director and the Director desires to be so appointed for such position and to perform the duties required
of such position in accordance with the terms and conditions of this Agreement.

 

AGREEMENT

 

In consideration for
the above recited promises and the mutual promises contained herein, the adequacy and sufficiency of which are hereby acknowledged,
the Company and the Director hereby agree as follows:

 

1. DUTIES.
The Company requires that the Director be available to perform the duties of a director customarily related to this function
as may be determined and assigned by the Board of Directors of the Company and as may be required by the Company’s
constituent instruments, including its certificate or articles of incorporation, bylaws and its corporate governance and
board committee charters, each as amended or modified from time to time, and by applicable law, including by the Delaware
General Corporation Law (the “DGCL”). The Director agrees to devote as much time as is necessary to
perform completely the duties as the Director of the Company. The Director will perform such duties described herein in
accordance with the general fiduciary duty of directors arising under the DGCL.

 

2.TERM.
The term of this Agreement shall commence as of the date of the Director’s appointment by the Board of Directors of the Company
and shall continue until the Director’s removal or resignation.

 

3.COMPENSATION.
The Director waives any right to compensation in connection with the services provided hereunder.

 

4.EXPENSES.
The Company will reimburse the Director for pre-approved reasonable business related expenses incurred in good faith in the performance
of the Director’s duties for the Company. Such payments shall be made by the Company upon submission by the Director of a
signed statement itemizing the expenses incurred. Such statement shall be accompanied by sufficient documentary matter to support
the expenditures.

 

5.CONFIDENTIALITY.
The Company and the Director each acknowledge that, in order for the intents and purposes of this Agreement to be accomplished,
the Director shall necessarily be obtaining access to certain confidential information concerning the Company and its affairs,
including, but not limited to business methods, information systems, financial data and strategic plans which are unique assets
of the Company (“Confidential Information”). The Director covenants not to, either directly or indirectly, in
any manner, utilize or disclose to any person, firm, corporation, association or other entity any Confidential Information.

 

 

 

    	 

    	 

    

 

6.NON-COMPETE.
During the term of this Agreement (the “Restricted Period”), the Director shall not, directly or indirectly,
(i) in any manner whatsoever engage in any capacity with any business competitive with the Company’s current lines of business
or any business then engaged in by the Company, any of its subsidiaries or any of its affiliates (the “Company's Business”)
for the Director’s own benefit or for the benefit of any person or entity other than the Company or any subsidiary or affiliate;
or (ii) have any interest as owner, sole proprietor, shareholder, partner, lender, director, officer, manager, employee, consultant,
agent or otherwise in any business competitive with the Company's Business; provided, however, that (x) this Clause
6 shall not be deemed to prohibit any investment activities of Warburg Pincus LLC and its affiliated funds and the Director’s
activities in connection therewith, provided further that the Director cannot act as a director in any company engaging in business
similar to or competing with the Company’s Business without the Company’s written consent, and (y) the Director may
hold, directly or indirectly, solely as an investment, not more than two percent (2%) of the outstanding securities of any person
or entity which are listed on any national securities exchange or regularly traded in the over-the-counter market notwithstanding
the fact that such person or entity is engaged in a business competitive with the Company's Business.

 

7.TERMINATION.
With or without cause, the Company and the Director may each terminate this Agreement at any time upon ten (10) days written notice,
and the Company shall be obligated to pay to the Director the compensation and expenses due up to the date of the termination.
Nothing contained herein or omitted herefrom shall prevent the shareholder(s) of the Company from removing the Director with immediate
effect at any time for any reason.

 

8.INDEMNIFICATION.
The Company shall indemnify, defend and hold harmless the Director, to the full extent allowed by the law of the State of Delaware,
and as provided by, or granted pursuant to, any charter provision, bylaw provision, agreement (including, without limitation, the
Indemnification Agreement executed herewith), vote of stockholders or disinterested directors or otherwise, both as to action in
the Director’s official capacity and as to action in another capacity while holding such office. The Company and the Director
are executing the Indemnification Agreement in the form attached hereto as Exhibit A.

 

9.EFFECT
OF WAIVER. The waiver by either party of the breach of any provision of this Agreement shall not operate as or be construed
as a waiver of any subsequent breach thereof.

 

10.NOTICE.
Any and all notices referred to herein shall be sufficient if furnished in

writing at the addresses specified on the signature
page hereto or, if to the Company, to the Company’s address as specified in filings made by the Company with the U.S. Securities
and Exchange Commission and if by fax to +8610 6598 3222.

 

    	2

    	 

    

 

11.GOVERNING
LAW. This Agreement shall be interpreted in accordance with, and the rights of the parties hereto shall be determined by, the
laws of the State of New York without reference to that state’s conflicts of laws principles.

 

12.ASSIGNMENT.
The rights and benefits of the Company under this Agreement shall be transferable, and all the covenants and agreements hereunder
shall inure to the benefit of, and be enforceable by or against, its successors and assigns. The duties and obligations of the
Director under this Agreement are personal and therefore the Director may not assign any right or duty under this Agreement without
the prior written consent of the Company.

 

13.MISCELLANEOUS.
If any provision of this Agreement shall be declared invalid or illegal, for any reason whatsoever, then, notwithstanding such
invalidity or illegality, the remaining terms and provisions of the this Agreement shall remain in full force and effect in the
same manner as if the invalid or illegal provision had not been contained herein.

 

14.ARTICLE
HEADINGS. The article headings contained in this Agreement are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Agreement.

 

15.COUNTERPARTS.
This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one instrument.
Facsimile execution and delivery of this Agreement is legal, valid and binding for all purposes.

 

16.ENTIRE
AGREEMENT. Except as provided elsewhere herein, this Agreement

sets forth the entire agreement of the parties with respect
to its subject matter and supersedes all prior agreements, promises, covenants, arrangements, communications, representations
or warranties, whether oral or written, by any officer, employee or representative of any party to this Agreement with respect
to such subject matter.

 

 

[Signature Page Follows]

 

    	3

    	 

    

 

 

IN WITNESS WHEREOF,
the parties hereto have caused this Director Agreement to be duly executed and signed as of the day and year first above written.

 

 

 

 

	 	 CHINA BIOLOGIC PRODUCTS, INC.
	 	 
	 	 
	 	By:	/s/ David Gao
	 	Name: David Gao
	 	Title: Chairman & Chief Executive Officer
	 	 
	 	 
	 	 
	 	DIRECTOR
	 	 
	 	 
	 	By:	 /s/ Dai Feng
	 	Name: Dai Feng
	 	 
		Address:

 

    	 

    	 

    

 

EXHIBIT A

 

Form of Indemnification Agreement

 

(See Attached)EXHIBIT 10.1

STONERIDGE, INC. 

AMENDED AND RESTATED

LONG-TERM INCENTIVE PLAN

 20XX PERFORMANCE SHARES AGREEMENT

 

Stoneridge, Inc., an Ohio corporation (the
“Company”), pursuant to the terms and conditions hereof, hereby grants to _____________ (“Grantee”) the
right to receive, depending on continued service and Company performance, _______ Common Shares (the “Target Award”),
without par value, of the Company (the “Performance Shares”), subject to the terms and conditions of this Agreement
(the “Agreement”). As set forth below, the grant of the Performance Shares is comprised of three separate mutually
exclusive parts, Target Award I, Target Award II and Target Award III.

 

1.          The
Performance Shares are in all respects subject to the terms, conditions and provisions of this Agreement and the Company’s
Amended and Restated Long-Term Incentive Plan (the “Plan”).

 

2.          The
right to receive the Performance Shares will be forfeited to the Company if the Grantee’s employment with the Company is
terminated prior to [Date], except in the case of (i) retirement, (ii) death, (iii) Permanent Disability, (iv) Change in Control
or (v) termination without cause, each as provided below.

 

If the employment of the Grantee is not
terminated prior to [Date], the Performance Shares shall, subject to satisfaction of the performance criteria applicable to Target
Awards II and III, be earned on [Date].

 

Special Provisions Applicable to Retirement.

 

Subject to the conditions below, in the case of retirement
the Performance Shares granted with respect to:

 

		(1)	Target Award I shall be earned on the date of retirement and a certificate or certificates representing Target Award I Performance
Shares shall promptly be delivered to the Grantee, but in no event shall be delivered later than the 15th day of the
third month following the year in which Performance Shares were earned;

 

		(2)	Target Award II shall be earned upon satisfaction of the performance criteria applicable to Target Award II, and a certificate
or certificates representing Target Award II Performance Shares shall be delivered to the Grantee as promptly as practical after
completion of the Peer Group Performance Period but in no event later than [Date]; and

 

		(3)	Target Award III shall be earned upon satisfaction of the performance criteria applicable to the Target Award III, and a certificate
or certificates representing Target Award III Performance Shares shall be delivered to the Grantee as promptly as practical after
completion of the EPS Performance Period but in no event later than [Date].

 

    	 

    	 

    

 

Only a Grantee who (i) is 63 or older on the date
of retirement, (ii) has provided written notice to the Compensation Committee of the Board of Directors (the “Committee”)
of the intent to retire at least one year prior to the retirement date, and (iii) has executed prior to retirement a customary
one year non-competition agreement shall be permitted to have his or her Performance Shares earned upon retirement.

 

If the employment of the Grantee is not
terminated prior to [Date], (the “Performance Period”) the Performance Shares shall be earned in the amounts set forth
below on [Date]:

 

Target Award I           Time-Based
Earning

 

	Number of Shares That May be Earned	 	 

 

Target Award II         Company Performance
Versus Peer Group Performance and Time-Based Earning

 

Depending on the achievement
of the Company’s total shareholder return (“TSR”) (as defined below) as compared to the Peer Group’s TSR
for the Company’s fiscal years 20XX, 20YY, and 20ZZ (the “Peer Group Performance Period”):

 

	Quartile	 	Percentile	 	 	Shares Earned	 
	1st	 	 	≥75%
-100%	 	 	 	______	 
	2nd	 	 	≥50% - <75%	 	 	 	______	 
	3rd	 	 	≥25% -< 50%	 	 	 	______	 
	4th	 	 	<25%	 	 	 	0	 

 

If the Company’s TSR for
the Peer Group Performance Period is between the upper and lower percentiles within a quartile, per the above table, the number
of shares earned shall be determined by interpolation between the corresponding percentiles as follows: the difference between
the actual percentile performance and the lower percentile in the applicable quartile shall be divided by 0.25, the resulting fraction
shall be multiplied by 50 and the resulting product, rounded to the nearest whole share, shall be added to the corresponding number
of shares in the above table for the immediately lower quartile, with the sum being the total shares earned. If the Company’s
TSR for the Peer Group Performance Period is exactly 50%, 75% or 100% of the Peer Group Performance then the number of shares earned
shall be the maximum amount for the respective quartile in the above table, as applicable.

 

The Peer Group companies are:
Accuride, American Axle & Manufacturing, Commercial Vehicle Group, CTS, EnPro Industries, Esterline Technologies, Gentex, Graco,
Littelfuse, Meritor, Inc., Modine Manufacturing, Standard Motor Products, Superior Industries, and Titan International. The Peer
Group shall be subject to modification at the discretion of the Committee from time to time, when events warrant. The performance
of the Peer Group companies shall not be weighted based on the size of the respective company.

 

Total shareholder return for both
the Company and the Peer Group companies shall be calculated by dividing: (i) the sum of (A) the cumulative amount of dividends
for the Peer Group Performance Period, and (B) the difference between the respective company’s share price at the end of
and the beginning of the Peer Group Performance Period; by (ii) the shares price at the beginning of the Peer Group Performance
Period.

 

    	2

    	 

    

 

Target Award III          EPS Performance and
Time-Based Earning

 

Depending on the Company’s
earnings per share (“EPS”) (as defined below) for the Company’s annual fiscal years of 20XX, 20YY, and 20ZZ (the
“EPS Performance Period”) and subject to the 20YY and 20ZZ Addenda to this Agreement:

 

	20XX 

EPS	 	Shares Earned	 	 	20YY EPS
 per
 Addendum	 	 	Shares Earned	 	 	20ZZ EPS
 per
 Addendum	 	 	Shares Earned	 
	≥  _____	 	 	______	 	 	 	TBD	 	 	 	______	 	 	 	TBD	 	 	 	______	 
	≥ _____*	 	 	______	 	 	 	 TBD*	 	 	 	______	 	 	 	TBD*	 	 	 	______	 
	≥  _____	 	 	______	 	 	 	TBD	 	 	 	______	 	 	 	TBD	 	 	 	______	 
	<  _____	 	 	0	 	 	 	TBD	 	 	 	0	 	 	 	TBD	 	 	 	0	 

 

TBD – To be provided in the 20YY and 20ZZ Addenda

*Target threshold

 

If the Company’s EPS for
any fiscal year is between two EPS data points, per the above table for that fiscal year, the number of shares earned shall be
determined by interpolation between those data points as follows: the difference between the actual EPS and the lower data point
shall be divided by the difference between the two data points, the resulting fraction shall be multiplied by the difference between
the two corresponding numbers of shares in the above table and the resulting product, rounded to the nearest whole share, shall
be added to the corresponding number of shares for the lower data point in the above table, with the sum being the total shares
earned.

 

The Company’s EPS for any
fiscal year in the EPS Performance Period shall mean the Company’s aggregate fully diluted earnings per Common Share for
that fiscal year calculated in accordance with generally accepted accounting principles, before extraordinary items, cumulative
effects of changes in accounting principles, adjustments for goodwill impairments and the tax effect thereof, if any, as set forth
on the audited consolidated financial statements of the Company for that fiscal year; provided, however, the EPS targets for any
year in the Performance Period may, at the Committee discretion, be adjusted as a result of any significant, unusual or one-time
expense or gain items that the Company could not have reasonably been expected to foresee.

 

The 20YY and 20ZZ Addenda to this
Agreement shall be appended to this Agreement and incorporated herein by reference, effective upon their respective adoption by
the Committee.

 

3.          If
earned, the Performance Shares for the respective Target Award will be issued in the name of the Grantee. The Company’s transfer
agent and/or share transfer records will show the Grantee as the owner of record of the Performance Shares as of the date the Performance
Shares are earned.  The certificate or certificates representing the Performance Shares earned may, at the Company's discretion,
be in uncertificated (electronic or book entry) form.

    	3

    	 

    

 

4.          Notwithstanding
the foregoing, in addition to earning the Performance Shares as set forth above, the Performance Shares shall be earned upon the
occurrence of an event and in the amounts as described below.

 

Target Award I shall be earned and not be
forfeited in the event of:

 

(a)          the
Grantee’s death or Permanent Disability in proportion to the number of months, including any partial month, elapsed in the
Performance Period divided by 36;

 

(b)          a
Change in Control or Potential Change in Control of the Company; or

 

(c)          the
termination “without cause” of the Grantee’s employment by the Company; provided, however only in proportion
to the number of months, including any partial month, elapsed in the Performance Period divided by 36.

 

A certificate or certificates representing
the earned Performance Shares granted under Award I shall be delivered to the Grantee or the Grantee’s estate after the occurrence
of an event described above as soon as practical, but in no event shall be delivered later than the 15th day of the
third month following the year in which Performance Shares were earned.

 

Target Award II shall be earned and not
be forfeited in the event of:

 

(a)          the
Grantee’s death or Permanent Disability in proportion to the number of months, including any partial month, elapsed in the
Peer Group Performance Period divided by 36;

 

(b)          a
Change in Control or Potential Change in Control of the Company; or

 

(c)          the
termination “without cause” of the Grantee’s employment by the Company; provided, however only in proportion
to the number of months, including any partial month, elapsed in the Peer Group Performance Period divided by 36.

 

In the event of the Grantee’s
death, Permanent Disability or termination without cause the shares granted in Target Award II shall be earned in amounts (and
subject to the 36 month pro rata earning provisions for death, Permanent Disability and termination without cause) in accordance
with the Company’s TSR during the Peer Group Performance Period as determined under the metrics of Target Award II above.
A certificate or certificates representing the earned Performance Shares under Target Award II shall be delivered to the Grantee
or the Grantee’s estate as promptly as practical after completion of the Peer Group but no in event later than [Date]. In
the event of a Change in Control or Potential Change in Control of the Company, Target Award II shall be earned in amounts which
assume the Company’s TSR during the Peer Group Performance Period is equal to the 50th percentile of the Peer
Group companies’ performance in that period. A certificate or certificates representing the earned Performance Shares under
Target Award II shall be delivered to the Grantee as promptly as practical after the Change in Control or Potential Change in Control,
but in no event shall be delivered later than the 15th day of the third month following the year in which Performance
Shares were earned.

 

    	4

    	 

    

 

Target Award III shall be earned and not
be forfeited in the event of:

 

(a)          the
Grantee’s death or Permanent Disability in proportion to the number of months, including any partial month, elapsed in the
EPS Performance Period divided by 36;

 

(b)          a
Change in Control of the Company; or

 

(c)          the
termination “without cause” of the Grantee’s employment by the Company; provided, however only in proportion
to the number of months, including any partial month, elapsed in the EPS Performance Period divided by 36.

 

In the event of the Grantee’s death,
Permanent Disability or termination without cause the Performance Shares granted under Target Award III shall be earned in amounts
(and subject to the 36 month pro rata earning provisions for death, Permanent Disability and termination without cause) in accordance
with the Company’s actual EPS for each of 20XX, 20YY, and 20ZZ target thresholds during the EPS Performance Period for Target
Award III. A certificate or certificates representing the earned Performance Shares under Target Award III shall be delivered to
the Grantee or the Grantee’s estate as promptly as practical after completion of the EPS Performance Period, but no in event
later than [Date]. In the event of a Change in Control of the Company, Target Award III shares shall be earned in amounts which
assume the Company’s EPS satisfied the respective 20XX, 20YY and 20ZZ at the specified target thresholds. A certificate or
certificates representing the earned Performance Shares under Target Award III shall be delivered to the Grantee as promptly as
practical after the Change in Control or Potential Change in Control, but in no event shall be delivered later than the 15th
day of the third month following the year in which Performance Shares were earned.

 

Termination shall be deemed to be “without
cause” unless the Board of Directors of the Company, or its designee, in good faith determines that termination is because
of any one or more of the following, in which case such termination shall be deemed to be for “cause”:

 

The Grantee’s:

 

		(a)	fraud;

 

		(b)	misappropriation of funds from the Company;

 

		(c)	commission of a felony or of an act or series of acts which result in material injury to the business reputation of the Company;

 

		(d)	commission of a crime or act or series of acts involving moral turpitude;

 

		(e)	commission of an act or series of repeated acts of dishonesty that are materially inimical to the best interests of the Company;

 

    	5

    	 

    

 

		(f)	willful and repeated failure to perform his duties, which failure has not been cured within fifteen (15) days after the Company
gives notice thereof to the Grantee;

 

		(g)	material breach of any material provision of an employment agreement, if any, which breach has not been cured in all substantial
respects within ten (10) days after the Company gives notice thereof to the Grantee; or

 

		(h)	failure to carry out the reasonable directions or instructions of the Grantee’s superiors, provided the directions or
instructions are consistent with the duties of the Grantee’s office, which failure has not been cured in all substantial
respects within ten (10) days after the Company gives notice thereof to the Grantee.

 

Provided, however, the Company’s obligation
to provide notice and an opportunity to cure, pursuant to subsections (f)-(h) above, shall only apply to the Grantee’s first
breach, first failure to perform or first failure to follow directions, as the case may be, of the nature giving rise to the right
of the Company to provide notice thereof. In addition, the Grantee may terminate his employment with the Company, and such termination
shall be deemed a termination by the Company “without cause” if:

 

		(a)	the Company reduces the Grantee’s title, responsibilities, power or authority in comparison with his title, responsibilities,
power or authority on the date hereof;

 

		(b)	the Company assigns the Grantee duties which are inconsistent with the duties assigned to the Grantee on the date hereof and
which duties the Company persists in assigning to the Grantee despite the prior written objection of the Grantee; or

 

		(c)	the Company reduces the Grantee’s annual base compensation (unless such decrease is proportionate with a decrease in
the base compensation of the officers of the Company as a group), or materially reduces his group health, life, disability or other
insurance programs, his pension, retirement or profit-sharing benefits or any benefits provided by the Company, or excludes him
from any plan, program or arrangement, including but not limited to bonus or incentive plans.

 

5.          On
any change in the number or kind of outstanding common shares of the Company by reason of a recapitalization, merger, consolidation,
reorganization, separation, liquidation, share split, share dividend, combination of shares or any other change in the corporate
structure or Common Shares of the Company, the Company, by action of the Committee, is empowered to make such adjustment, if any,
in the number and kind of Performance Shares subject to this Agreement as it considers appropriate for the protection of the Company
and of the Grantee.

 

    	6

    	 

    

 

6.          No
later than the date as of which an amount first becomes includable in the gross income of the Grantee for federal income tax purposes
with respect to the Performance Shares granted hereunder, the Grantee shall pay to the Company, or make arrangements satisfactory
to the Committee regarding the payment of, any federal, state or local taxes of any kind required by law to be withheld with respect
to that amount. Unless otherwise determined by the Committee, minimum statutory withholding obligations may be settled with previously
owned Common Shares or Performance Shares that have been earned. The making of that payment or those arrangements is a condition
to the obligations of the Company under the Plan, and the Company and its subsidiaries and affiliates may, to the extent permitted
by law, deduct any taxes from any payment of any kind otherwise payable to the Grantee.

 

7.          Nothing
in this Agreement shall affect in any manner any conflicting or other provision of any other agreement between the Grantee and
the Company. Nothing contained in this Agreement shall limit whatever right the Company might otherwise have to terminate the employment
of the Grantee.

 

8.          The
laws of the State of Ohio govern this Agreement, the Plan and the Performance Shares granted hereby.

 

IN WITNESS WHEREOF, the Company has caused
its corporate name to be subscribed by its duly authorized officer as of the ___ day of _________ 20XX.

 

	 	 	STONERIDGE, INC.
	 	 	 	 
	 	 	By	 
	 	 	 	John C. Corey
	 	 	 	 
	The foregoing is hereby accepted.	 	 	 
	 	 	 	 
	 	 	 	 

 

    	7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}]]